Our findings are consistent with those of other studies, which have reported higher PD-L1 expression in EBV-positive HL, emphasizing the potential therapeutic implications of targeting the PD-1/PD-L1 axis in these patients. Here, CD274 is linked to Hodgkins lymphoma.